New lung cancer drug challenges standard treatment in major trial
NCT ID NCT05499390
Summary
This large Phase 3 trial compares a new drug called AK112 against the established treatment pembrolizumab for people with advanced non-small cell lung cancer. It aims to see if AK112 can better control the cancer and help patients live longer without their disease getting worse. The study includes 398 adults with specific types of advanced lung cancer who haven't had prior treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.